Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study
Authors:
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 31 (12) , 1764-1772
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 24 references indexed in Scilit:
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2017
- Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordanceAnnals of Oncology, 2017
- Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder CancerEuropean Urology, 2017
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Genomic Alterations in Liquid Biopsies from Patients with Bladder CancerEuropean Urology, 2016
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerEuropean Urology, 2015
- COSMIC: exploring the world's knowledge of somatic mutations in human cancerNucleic Acids Research, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 studyThe Lancet Oncology, 2013